Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation technique that uses rapidly changing magnetic fields to induce electrical currents in cortical [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--. Repetitive TMS (rTMS) can produce lasting changes in cortical excitability and [synaptic plasticity[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--—enhancing or suppressing neural activity depending on stimulation parameters—making it both a powerful research tool for probing brain circuit function and a potential therapeutic intervention for [neurodegenerative /diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases.
In the context of neurodegeneration, TMS serves dual roles: as a diagnostic biomarker revealing patterns of cortical excitability that can distinguish disease subtypes and predict progression, and as a therapeutic modality aimed at restoring disrupted circuit function and enhancing cognitive or motor performance. The U.S. FDA has cleared TMS devices for depression and OCD, and clinical trials are actively evaluating efficacy in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (AD), [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- (PD), [amyotrophic lateral sclerosis[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- (ALS), and other conditions (Cantone et al., 2014).
¶ Single-Pulse and Paired-Pulse TMS
A brief, intense current through a coil placed on the scalp generates a magnetic field pulse (1-2 Tesla at the coil surface) that penetrates the skull and induces an electrical current in underlying [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--. Key neurophysiological measures include:
- Motor evoked potential (MEP): Amplitude and latency of the muscle response to a TMS pulse over motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, reflecting corticospinal excitability
- Resting motor threshold (RMT): Minimum stimulation intensity to produce MEPs, reflecting cortical membrane excitability
- Short-interval intracortical inhibition (SICI): Paired-pulse measure reflecting [GABAergic] inhibition (GABA_A receptor-mediated)
- Intracortical facilitation (ICF): Paired-pulse measure reflecting [glutamatergic] excitation
- Short-afferent inhibition (SAI): Reflects [cholinergic] circuits in sensorimotor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--
- Long-interval intracortical inhibition (LICI): Reflects GABA_B receptor-mediated inhibition
Repeated trains of TMS pulses produce effects that outlast the stimulation period:
| Protocol |
Frequency |
Effect |
Duration |
| Low-frequency rTMS |
1 Hz |
Cortical inhibition (LTD-like) |
15-60 min |
| High-frequency rTMS |
5-20 Hz |
Cortical excitation ([LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- |
15-60 min |
| Theta burst stimulation (TBS) |
50 Hz bursts at 5 Hz |
Variable (cTBS: inhibition; iTBS: excitation) |
30-60 min |
| Deep TMS (H-coil) |
Variable |
Deeper cortical/subcortical reach |
Variable |
These plasticity-like effects are mediated by [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor]] receptor]-dependent mechanisms analogous to [long-term potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- ([LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX-- and long-term depression (LTD) (Huang et al., 2005).
TMS reveals a distinctive neurophysiological signature in AD:
- Reduced RMT: Cortical hyperexcitability, reflecting loss of [cholinergic] and [GABAergic] inhibition
- Reduced SICI: Impaired intracortical inhibition (GABA_A circuit dysfunction)
- Impaired SAI: Specific deficit in cholinergic short-afferent inhibition—the most reliable TMS biomarker of AD, normalizable by [cholinesterase inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors--TEMP--/entities)--FIX-- (Di Lazzaro et al., 2006)
- Enhanced [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX---like plasticity (early): Compensatory enhancement in mild cognitive impairment (MCI)
- Impaired [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX---like plasticity (late): Failed plasticity in moderate-severe AD
SAI deficits can distinguish AD from other dementias including [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- and [DLB], and may be detectable in preclinical stages (Benussi et al., 2023).
In PD, TMS reveals:
- Normal or increased RMT: Unlike AD
- Reduced SICI: Reflecting impaired [dopaminergic] modulation of GABAergic inhibition
- Abnormal cortical plasticity: Impaired [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX---like and LTD-like responses, reflecting [striatal] and cortical circuit dysfunction
- Improved SICI with levodopa: [Levodopa[/treatments/[levodopa[/treatments/[levodopa[/treatments/[levodopa--TEMP--/treatments)--FIX-- and [dopamine agonists[/treatments/[dopamine-agonists[/treatments/[dopamine-agonists[/treatments/[dopamine-agonists--TEMP--/treatments)--FIX-- partially normalize SICI deficits
TMS is a valuable diagnostic and prognostic tool in ALS:
- Cortical hyperexcitability: Reduced RMT, reduced SICI, and increased ICF appear early—often before clinical weakness—and distinguish ALS from mimics
- Central motor conduction time: Prolonged in ALS, reflecting corticospinal tract degeneration
- Split hand index: TMS-derived measure of differential hand muscle involvement, characteristic of ALS
- Threshold tracking TMS: A specialized technique providing quantitative cortical excitability profiles that can identify ALS in the diagnostic evaluation (Vucic et al., 2008)
[Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- shows:
- Reduced SICI: Progressive loss of intracortical inhibition correlating with disease stage
- Impaired cortical plasticity: Abnormal [LTP[/entities/[long-term-potentiation[/entities/[long-term-potentiation[/entities/[long-term-potentiation--TEMP--/entities)--FIX--/LTD-like responses to rTMS protocols
- Prolonged cortical silent period: Reflecting altered GABA_B signaling
Personalized TMS protocols use structural MRI, fMRI, or EEG to:
- Identify optimal stimulation targets based on individual functional connectivity
- Adjust intensity based on cortical-to-coil distance
- Monitor real-time neural responses to optimize parameters
Combining [focused ultrasound[/treatments/[focused-ultrasound[/treatments/[focused-ultrasound[/treatments/[focused-ultrasound--TEMP--/treatments)--FIX-- with TMS may enable non-invasive modulation of deeper brain structures beyond the reach of conventional TMS coils.
A complementary non-invasive stimulation technique using weak direct current (1-2 mA) to modulate cortical excitability. Anodal tDCS enhances excitability while cathodal tDCS reduces it. tDCS has been evaluated in AD, PD, and ALS with modest results.
Adaptive stimulation systems that monitor ongoing neural activity (via EEG) and deliver TMS pulses timed to specific brain states (e.g., theta phase) to maximize plasticity-enhancing effects.
¶ Safety and Limitations
TMS is generally safe with few serious adverse effects:
- Common: Scalp discomfort, headache, mild facial twitching during stimulation
- Uncommon: Syncope (vasovagal)
- Rare: Seizure induction (primarily with high-frequency protocols; risk ~0.01%)
- Contraindications: Metallic implants near the coil, cochlear implants, epilepsy history
- Limited depth of penetration: Standard coils reach 1.5-2 cm below the skull; deep structures ([hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--, [substantia nigra) cannot be directly stimulated
- Variable responses: Inter-individual variability in response to rTMS is high (~50% non-responders)
- Short duration of effects: Therapeutic effects typically last days to weeks, requiring repeated sessions
- Small effect sizes: Meta-analyses show statistically significant but clinically modest cognitive improvements in AD
- Lack of blinding: Sham conditions are imperfect due to scalp sensation
- Accelerated protocols: Multiple daily sessions (e.g., Stanford neuromodulation protocol) to produce faster and larger effects
- Biomarker-guided treatment: Using SAI or other TMS measures to select patients most likely to respond
- Combination therapies: TMS + [cholinesterase inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors--TEMP--/entities)--FIX-- + cognitive training
- Multi-target stimulation: Simultaneous or sequential stimulation of connected network nodes
- Home-based TMS: Portable devices for maintenance therapy following clinic-based induction
- [Deep Brain Stimulation (DBS)[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation--TEMP--/treatments)--FIX--
- [Focused Ultrasound Therapy for Neurodegenerative Diseases[/treatments/[focused-ultrasound[/treatments/[focused-ultrasound[/treatments/[focused-ultrasound--TEMP--/treatments)--FIX--
The study of Transcranial Magnetic Stimulation (Tms) For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Cantone M, Di Pino G, Capone F, et al. (2014]. The contribution of transcranial magnetic stimulation in the diagnosis and in the management of dementia. Clin Neurophysiol, 125(8):1509-1532. PubMed)
- PubMed
- [Di Lazzaro V, Oliviero A, Pilato F, et al. (2006]. Neurophysiological predictors of long term response to AChE inhibitors in AD patients. J Neurol Neurosurg Psychiatry, 76(8):1064-1069. PubMed)
- [Benussi A, Cantoni V, Grassi M, et al. (2023]. Transcranial magnetic stimulation as a diagnostic tool in mild cognitive impairment: A systematic review. Neurology, 101. PMC)
- [Vucic S, Nicholson GA, Kiernan MC (2008]. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain, 131(Pt 6):1540-1550. PubMed)
- [Koch G, Casula EP, Bonnì S, et al. (2023]. Transcranial magnetic stimulation effects on cognitive enhancement in mild cognitive impairment and [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: a systematic review and meta-analysis. Front Neurol, 14:1209205. [PMC)(https://pmc.ncbi.nlm.nih.gov/articles/PMC10389278/)
- [Antonioni A, Bhatt S, Bhatt R, et al. (2025]. The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Alzheimers Dement. [Wiley)(https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.70337)
- [Sun W, Bi H, Qi Z, et al. (2025]. Status and trends of transcranial magnetic stimulation research in Alzheimer's Disease: A bibliometric and visual analysis. J Alzheimers Dis. SAGE)
- [Barker AT, Jalinous R, Freeston IL (1985]. Non-invasive magnetic stimulation of human motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--. Lancet, 1(8437):1106-1107. [PubMed)(https://pubmed.ncbi.nlm.nih.gov/2860322/)
- [Rossi S, Hallett M, Rossini PM, et al. (2009]. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol, 120(12):2008-2039. PubMed)
- [Lefaucheur JP, Aleman A, Baeken C, et al. (2020]. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin Neurophysiol, 131(2):474-528. PubMed)
- PubMed